| Bioactivity | CAY10580 is a potent and selective prostaglandin EP4 receptor agonist (Ki=35 nM)[1]. |
| Invitro | CAY10580 (10-10000 nM; 40 min) significantly increases apical membrane abundance of AQP2 in MDCK cells at 100 to 10000 nM[2]. |
| In Vivo | CAY10580 (200 μg/kg body weight; i.p; daily for three weeks) effectively prevents diet-induced hypercholesterolemia, enhances endogenous bile acid synthesis and their fecal excretion[3]. Animal Model: |
| Name | CAY10580 |
| CAS | 64054-40-6 |
| Formula | C19H35NO4 |
| Molar Mass | 341.49 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Solution, -20°C, 2 years |
| Reference | [1]. Billot X, et al. Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett. 2003;13(6):1129-1132. [2]. Olesen ET, et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A. 2011;108(31):12949-12954. [3]. Ying F, et al. EP4 emerges as a novel regulator of bile acid synthesis and its activation protects against hypercholesterolemia. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(9):1029-1040. |